RARRES2 and metabolic syndrome: The assessment of the concentration of chemerin in the youngest age group concerned only small for gestational age (SGA) infants, which is a risk factor for metabolic alterations (type 2 diabetes, insulin resistance, arterial hypertension, obesity and dyslipidemia in adulthood).